Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 11/20 | 0.49 |
| ▸ | CDK2 | P24941 | 3/20 | 0.45 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.41 |
| ▸ | CDK4 | P11802 | 1/20 | 0.41 |
| ▸ | PRKACA | P17612 | 1/20 | 0.41 |
| ▸ | PRKACG | P22612 | 1/20 | 0.41 |
| ▸ | PRKACB | P22694 | 1/20 | 0.41 |
| ▸ | CCND1 | P24385 | 1/20 | 0.41 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.41 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | QPCT | Q16769 | 1/20 | 0.40 |
| ▸ | PRKCA | P17252 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7535498 | 0.86 | GSK3B (0.46) | GSK3BCDK2KDM4EALDH1A1PRKCA | |
| SCHEMBL4417375 | 0.82 | GABRP (0.49) | GSK3BCDK2ALDH1A1QPCTPRKCA | |
| SCHEMBL8162074 | 0.77 | MAPT (0.54) | CDK2CCNE2CDK4CCND1CCNE1 | |
| SCHEMBL8162898 | 0.73 | CCNE2 (0.72) | GSK3BCDK2CCNE2CDK4CCND1 | |
| SCHEMBL22450636 | 0.71 | BRD4 (0.51) | GSK3BCDK2CCNE2CDK4PRKACA | |
| SCHEMBL15024957 | 0.71 | CCNE2 (0.49) | GSK3BCDK2CCNE2CDK4CCND1 | |
| SCHEMBL4421751 | 0.70 | GSK3B (0.61) | GSK3BCDK2QPCTPRKCA | |
| SCHEMBL4419603 | 0.70 | GSK3B (0.49) | GSK3BCDK2CCNE2CDK4CCND1 | |
| SCHEMBL4425448 | 0.69 | GSK3B (0.51) | GSK3BCDK2CDK4CCND1ALDH1A1 | |
| SCHEMBL8161370 | 0.69 | CCNT1 (0.56) | GSK3BCDK2CCNE2CDK4CCND1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020052397-A1 | 3-indolyl-4-phenyl-1H-pyrrole-2,5-dione derivatives as inhibitors of glycogen synthase kinase-3beta | SYNTEX (U.S.A.) LLC | 2002-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020052397-A1 | 3-indolyl-4-phenyl-1H-pyrrole-2,5-dione derivatives as inhibitors of glycogen synthase kinase-3beta | GSK3B, GSK3A, PYGL | GSK3B 1/4885CDK2 102/4885CCNE2 1424/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.